Get the Stockscreener App
5.08
0.99%
+0.05
After Hours:
5.08
Moleculin Biotech Inc stock is currently priced at $5.08, with a 24-hour trading volume of 8,388.
It has seen a +0.99% increased in the last 24 hours and a +18.69% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.05 pivot point. If it approaches the $5.16 resistance level, significant changes may occur.
Previous Close:
$5.03
Open:
$5.14
24h Volume:
8,388
Market Cap:
$11.74M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-5.0297
EPS:
-1.01
Net Cash Flow:
$-24.23M
1W Performance:
+6.72%
1M Performance:
+18.69%
6M Performance:
+761.02%
1Y Performance:
+696.86%
1D Range:
$5.0203
$5.14
52W Range:
$0.3377
$6.24
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713 300 5160
Address
5300 Memorial Drive, Suite 950, Houston, TX
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech Inc says Donald Picker will no longer serve as president or COO of co - Reuters
Reuters
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid ... - The Malaysian Reserve
The Malaysian Reserve
Moleculin Biotech to Present Research at EHA2024 Hybrid Congress - TipRanks.com - TipRanks
TipRanks
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid ... - PR Newswire
PR Newswire
Moleculin begins NIH-funded Phase II glioblastoma treatment trial - Yahoo Finance
Yahoo Finance
Q2 2024 EPS Estimates for Moleculin Biotech, Inc. (NASDAQ:MBRX) Boosted by Roth Capital - Defense World
Defense World
Moleculin Biotech Inc Stock (MBRX) Financials Data
Moleculin Biotech Inc (MBRX) Net Income 2024
MBRX net income (TTM) was -$29.77 million for the quarter ending December 31, 2023, a -2.56% decrease year-over-year.
Moleculin Biotech Inc (MBRX) Cash Flow 2024
MBRX recorded a free cash flow (TTM) of -$24.23 million for the quarter ending December 31, 2023, a +12.56% increase year-over-year.
Moleculin Biotech Inc (MBRX) Earnings per Share 2024
MBRX earnings per share (TTM) was -$15.30 for the quarter ending December 31, 2023, a +0.00% growth year-over-year.
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
0.77%
1.20%
Cap:
|
Volume (24h):